Jun 16, 2020
Provention Bio Announces Proposed Public Offering of Common Stock
Jun 15, 2020
Provention Bio's Teplizumab Continued to Significantly Delay the Onset of Insulin-Dependent Type 1 Diabetes (T1D) in Presymptomatic Patients
May 28, 2020
Provention Bio to Present at the Jefferies Virtual Healthcare Conference
May 20, 2020
Provention Bio Announces Changes to its Board of Directors
Apr 30, 2020
Provention Bio to Report First Quarter 2020 Financial Results and Host Conference Call on Thursday, May 7, 2020
Mar 16, 2020
Provention Bio Provides Update on the Status of Its Phase 3 PROTECT Study for the Treatment of Newly Diagnosed Type 1 Diabetes
Mar 12, 2020
Provention Announces Positive Data from Phase 1b PREVAIL Study of PRV-3279
Mar 12, 2020
Provention Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Mar 05, 2020
Provention Bio to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, March 12, 2020
Nov 05, 2019
Provention Bio Reports Third Quarter 2019 Financial Results
Sep 26, 2019
Sean Doherty Joins Provention Bio Board of Directors
Sep 24, 2019
Provention Bio Reiterates Regulatory Strategy for PRV-031 and Announces Completion of Follow-on Financing
Aug 20, 2019
Provention Bio Announces Key Addition to its Leadership Team
Aug 06, 2019
Provention Bio Reports Second Quarter 2019 Financial Results
Aug 05, 2019
Provention Bio Announces Breakthrough Therapy Designation for Teplizumab (PRV-031) for the Prevention or Delay of Clinical Type 1 Diabetes in At-Risk Individuals
Jul 10, 2019
MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China
Jul 01, 2019
ActoBio Therapeutics(TM) Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 Diabetes
Jun 09, 2019
TrialNet Announces Type 1 Diabetes Prevention Breakthrough--
Jun 09, 2019
Teplizumab Delays Clinical Diagnosis of Type 1 Diabetes an Average of Two Years, According to Study Presented at ADA's Scientific Sessions
Jun 09, 2019
A Single Course of Provention's PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least Two Years